These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38973128)

  • 21. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
    Johnson RJ; Bakris GL; Borghi C; Chonchol MB; Feldman D; Lanaspa MA; Merriman TR; Moe OW; Mount DB; Sanchez Lozada LG; Stahl E; Weiner DE; Chertow GM
    Am J Kidney Dis; 2018 Jun; 71(6):851-865. PubMed ID: 29496260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Liu S; Perez-Ruiz F; Miner JN
    Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into the relationship between serum uric acid and pulmonary hypertension (Review).
    Zhou Y; Chen M; Zheng J; Shui X; He Y; Luo H; Lei W
    Mol Med Rep; 2024 Jan; 29(1):. PubMed ID: 37997855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uric acid and cardiovascular disease: A clinical review.
    Saito Y; Tanaka A; Node K; Kobayashi Y
    J Cardiol; 2021 Jul; 78(1):51-57. PubMed ID: 33388217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk.
    Borghi C; Agnoletti D; Cicero AFG; Lurbe E; Virdis A
    Hypertension; 2022 Sep; 79(9):1927-1936. PubMed ID: 35658505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uric acid in metabolic syndrome: From an innocent bystander to a central player.
    Kanbay M; Jensen T; Solak Y; Le M; Roncal-Jimenez C; Rivard C; Lanaspa MA; Nakagawa T; Johnson RJ
    Eur J Intern Med; 2016 Apr; 29():3-8. PubMed ID: 26703429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Insights of Soluble Uric Acid-related Kidney Disease.
    Pan J; Shi M; Ma L; Fu P
    Curr Med Chem; 2020; 27(30):5056-5066. PubMed ID: 30526453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
    Crawley WT; Jungels CG; Stenmark KR; Fini MA
    Redox Biol; 2022 May; 51():102271. PubMed ID: 35228125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
    Juraschek SP; Appel LJ; Miller ER
    Am J Hypertens; 2017 Sep; 30(9):871-875. PubMed ID: 28830083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperuricaemia and vascular risk: the debate continues.
    Landolfo M; Borghi C
    Curr Opin Cardiol; 2019 Jul; 34(4):399-405. PubMed ID: 30925517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential role of uric acid - The purpose or cause of cardiovascular diseases?
    Siemińska E; Sobczak P; Skibińska N; Sikora J
    Med Hypotheses; 2020 Sep; 142():109791. PubMed ID: 32434129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum uric acid levels and cardiovascular disease: the Gordian knot.
    Martínez-Quintana E; Tugores A; Rodríguez-González F
    J Thorac Dis; 2016 Nov; 8(11):E1462-E1466. PubMed ID: 28066631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uric acid transport and disease.
    So A; Thorens B
    J Clin Invest; 2010 Jun; 120(6):1791-9. PubMed ID: 20516647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Eliseev MS; Novikova AM
    Ter Arkh; 2019 May; 91(5):120-128. PubMed ID: 32598686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Effects of Elevated Serum Uric Acid Levels on Hypertension: A Scoping Review of Hyperuricemia.
    Ubhadiya TJ; Dubey N; Sojitra MH; Shah K; Joshi S; Gandhi SK; Patel P
    Cureus; 2023 Aug; 15(8):e43361. PubMed ID: 37701002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.